“… [74c,85] A number of these highly selective as well as several less selective inhibitors and compounds with undetermined selectivity of the same chemotype were co‐crystallized with zebrafish HDAC6: nexturastat A (PDB IDs: 5G0I, 5G0J), HPOB (PDB ID: 5EF7), HPB (PDB ID: 5WGK), peptoid‐based inhibitors ( 6 and others, PDB IDs: 6DVL, 6DVM, 6DVN), ACY‐1083 (PDB ID: 5WGM), bavarostat (PDB ID: 6DVO), imidazopyridine derivative MAIP‐032 (PDB ID: 6CGP), phenothiazine derivative KV70 (PDB ID: 5W5K), dual HDAC‐proteasome inhibitor RTS‐V5 ( 68 , PDB ID: 6CW8), broad‐spectrum HDAC inhibitor AR‐42 ( 69 , PDB IDs: 6UO3, 6UO5, 6UO7), givinostat ( 70 , PDB ID: 6UOC), bishydroxamic acid ( 71 , PDB ID: 6VNR) and diverse inhibitors (compounds 72 – 74 , PDB IDs: 6PZO, 6PZS, 6PZU; Figure 4). [18g–i,76,85h,j,86] The experimentally obtained binding modes shed light on the protein‐ligand interactions and structure–activity relationships of these compounds. Strikingly, and in contrast to typically observed bidentate binding of hydroxamic acids with alkyl and vinyl linkers, all listed benzhydroxamic acids are bound in a monodentate fashion except bavarostat ( 63 ), AR‐42 ( 69 , PDB ID: 6UO3) and givinostat ( 70 ).…”